CRISPR enhances cancer immunotherapy

The FDA recently approved the first cellular immunotherapies to treat certain blood cancers. But so far, these T cell immunotherapies can’t be used if the T cells themselves are cancerous. Such ‚CAR-T‘ cells kill each other because they resemble one another so closely. Scientists now have used the gene-editing technology CRISPR to engineer human T cells that can attack human T cell cancers without succumbing to friendly fire. (Mehr in: Cancer News — ScienceDaily)